血滞通胶囊联合匹伐他汀治疗高脂血症患者的疗效观察  

Observation of curative effect of Xuezhitong capsule combined with pitavastatin on hyperlipidemia patients

作　　者：曾满生 王雁南 罗俊芳 石秀明 黎星 邓婷婷 朱桂芳 华永平 ZENG Mansheng;WANG Yannan;LUO Junfang;SHI Xiuming;LI Xing;DENG Tingting;ZHU Guifang;HUA Yongping(Department of Cardiology,Jingdezhen Third People′s Hospital in Jiangxi Province,Jingdezhen 333000,China)

机构地区：[1]江西省景德镇市第三人民医院心内科,江西景德镇333000

出　　处：《中国现代医生》2021年第31期52-55,共4页China Modern Doctor

基　　金：江西省中医药科研项目(2019B196)。

摘　　要：目的探讨血滞通胶囊联合匹伐他汀治疗高脂血症患者的疗效。方法选取2019年3月至2020年11月景德镇市第三人民医院收治的120例高脂血症患者纳入研究对象,采用随机数字表法分为观察组与对照组,每组各60例,分别实施血滞通胶囊联合匹伐他汀治疗与单纯匹伐他汀治疗。比较两组患者治疗前后的血脂指标及临床效果。结果两组患者治疗前血脂指标比较,差异无统计学意义(P>0.05),观察组患者治疗后TG、TC、LDL-C指标分别为(2.08±0.54)mmol/L、(3.31±0.23)mmol/L、(2.03±0.44)mmol/L,低于对照组的(2.94±0.58)mmol/L、(4.41±0.30)mmol/L、(3.15±0.33)mmol/L,观察组HDL-C为(1.24±0.21)mmol/L,高于对照组的(0.94±0.25)mmol/L,差异有统计学意义(P<0.05);观察组患者治疗总有效率为93.3%,高于对照组的70.0%,差异有统计学意义(P<0.05);观察组患者不良反应总发生率为6.7%,与对照组的13.3%比较,差异无统计学意义(P>0.05)。结论血滞通胶囊联合匹伐他汀治疗高脂血症,对患者血脂指标改善作用显著,疗效可靠,可予以推广。Objective To explore the curative effect of Xuezhitong capsule combined with pitavastatin on hyperlipidemia patients.Methods A total of 120 hyperlipidemia patients who were admitted to Jingdezhen Third People′s Hospital from March 2019 to November 2020 were included in the study.The patients were divided into two groups,the observation group and the control group,by the random number table method,with 60 patients in each group,who were respectively treated with Xuezhitong capsule combined with pitavastatin and pitavastatin alone.Blood lipid indicators and clinical effects were compared between the two groups before and after treatment.Results Before treatment,no significant differences were observed in blood lipid indicators between the two groups(P>0.05).After treatment,the indicators of TG,TC and LDL-C in the observation group were(2.08±0.54)mmol/L,(3.31±0.23)mmol/L and(2.03±0.44)mmol/L,respectively,which were lower than(2.94±0.58)mmol/L,(4.41±0.30)mmol/L and(3.15±0.33)mmol/L in the control group,and the differences were statistically significant(P<0.05).The HDL-C of the observation group was(1.24±0.21)mmol/L,which was higher than(0.94±0.25)mmol/L of the control group,and the difference was statistically significant(P<0.05).The total effective rate of the observation group was 93.3%,which was higher than 70.0%of the control group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 6.7%,and no statistically significant difference was observed compared with 13.3%in the control group(P>0.05).Conclusion Xuezhitong capsule combined with pitavastatin in the treatment of hyperlipidemia has a significant effect on the improvement of blood lipid indicators of patients,with reliable efficacy,which can be popularized.

关 键 词：血滞通胶囊 匹伐他汀 高脂血症 血脂指标 LDL-C水平 

分 类 号：R544.1[医药卫生—心血管疾病]